New member | Kalsiom

10 June 2020

Targeting calcium signaling to cure auto-immune diseases

KALSIOM is a biotech company founded in April 2020 in Brest, France, discovering and developing first-in-class therapies to treat auto-immunes disorders (AID) involving B-cell dysfunction with a high medical need. The company is focusing on developing first-in-class monoclonal antibodies modulating calcium-signaling pathways in lymphocytes.